Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Celgene
Age
18–any
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
Must have histologically or cytologically confirmed adenocarcinoma of the prostate
Progressed on androgen deprivation therapy (ADT) and at least one prior secondary hormonal therapy approved for castration-resistant prostate cancer (CRPC)
Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1
You may not be if
Prior treatment with an androgen receptor (AR) degrader
Concurrent malignancy (present during screening) requiring treatment or history of prior malignancy active within 1 year prior to the first dose of IP
Clinically significant venous thromboembolism within 3 months prior to the first dose of IP
Any significant medical condition, such as uncontrolled infection, laboratory abnormality, or psychiatric illness
Clareo Health | Study to Evaluate the Safety and Tolerability of CC-94676 in Participants With Metastatic Castration-Resistant Prostate Cancer
